Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Innovhem


4 rue Pierre Fontaine
91000 Evry-Courcouronnes – FRANCE

Email : marie.cambot@innovhem.life
Marie Cambot : CEO
Web Site (french) >
Innovhem - Entreprise génopolitaine Innovhem - Entreprise génopolitaine

BoosterShaker#Diagnostics #Health / Well-being

  • Sickle cell disease
  • Red blood cell
  • Biomarkers
  • Predictive algorithm

Field of Activity


Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

HISTORY

INNOVHEM was created in October 2019 to join the Genopole Booster program.

With our expertise, we are developing the measurement of new bio-markers, which, in combination with artificial intelligence, will allow to assess the severity of the disease and to predict it.

TECHNOLOGY

From 2020, INNOVHEM proposes to perform bioassays to measure fetal hemoglobin and intravascular hemolysis (the degradation of red blood cells), as a service for pharmaceutical companies.

These biomarkers are used to evaluate the efficacy of treatments under development. In parallel, INNOVHEM develops tools that combine the measurement of these biomarkers with AI to allow clinicians to improve patient management.

Achievements/ Collaborations/ Milestones

INNOVHEM has signed a contract that provides the exclusive and worldwide exploitation of 3 patents that cover the two innovations originating from academic research (measurement of HbF by red blood cell and intra-vascular hemolysis).

INNOVHEM has also set up collaborations with institutions (Inserm, APHP, UPEC and EFS) for the research and development of these innovations. At the end of November 2020, INNOVHEM signed a first contract for a research study, funded by a private company.

Finally, in mid-December 2020, INNOVHEM recruited its first project manager.

  • Further Information

    3 Patents

    Strengths
    – Strong partnership with academic research
    – Close relations with industrials

     

     

Share
Genopole’s Companies

#Diagnostic


In same field

Cell Environment - Genopole's company

Cell Environment

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

Discover
Logo Integragen - Genopole's Company

Integragen

IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

Discover
logo GenoSplice - Genopole's Company

GenoSplice

Bioinformatics service provider (gene expression, splicing, SNP, CNV, epigenetics, data integration).

Discover
Endodiag - Genopole's company

Endodiag

Design, development and commercialization of medical devices and services for the diagnosis of endometriosis.

Discover
Enalees - Genopole's company

Enalees

Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.

Discover
AgenT Biotech - entreprise génopolitaine

AgenT

AgenT is developing an unprecedented blood test to identify patients with Alzheimer's disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer's disease.

Discover
View all >
With the support from